Loading…

Antibiotics for community-acquired pneumonia in children

Pneumonia caused by bacterial pathogens is the leading cause of mortality in children in low-income countries. Early administration of antibiotics improves outcomes. To identify effective antibiotic drug therapies for community-acquired pneumonia (CAP) of varying severity in children by comparing va...

Full description

Saved in:
Bibliographic Details
Published in:Cochrane database of systematic reviews 2013-06, Vol.2013 (6), p.CD004874-CD004874
Main Authors: Lodha, Rakesh, Kabra, Sushil K, Pandey, Ravindra M
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4734-6f71160393800a19d14e3d9748875fc6cab4f194d5dcda56c100cb43c001a1ce3
cites
container_end_page CD004874
container_issue 6
container_start_page CD004874
container_title Cochrane database of systematic reviews
container_volume 2013
creator Lodha, Rakesh
Kabra, Sushil K
Pandey, Ravindra M
description Pneumonia caused by bacterial pathogens is the leading cause of mortality in children in low-income countries. Early administration of antibiotics improves outcomes. To identify effective antibiotic drug therapies for community-acquired pneumonia (CAP) of varying severity in children by comparing various antibiotics. We searched CENTRAL 2012, Issue 10; MEDLINE (1966 to October week 4, 2012); EMBASE (1990 to November 2012); CINAHL (2009 to November 2012); Web of Science (2009 to November 2012) and LILACS (2009 to November 2012). Randomised controlled trials (RCTs) in children of either sex, comparing at least two antibiotics for CAP within hospital or ambulatory (outpatient) settings. Two review authors independently extracted data from the full articles of selected studies. We included 29 trials, which enrolled 14,188 children, comparing multiple antibiotics. None compared antibiotics with placebo.Assessment of quality of study revealed that 5 out of 29 studies were double-blind and allocation concealment was adequate. Another 12 studies were unblinded but had adequate allocation concealment, classifying them as good quality studies. There was more than one study comparing co-trimoxazole with amoxycillin, oral amoxycillin with injectable penicillin/ampicillin and chloramphenicol with ampicillin/penicillin and studies were of good quality, suggesting the evidence for these comparisons was of high quality compared to other comparisons.In ambulatory settings, for treatment of World Health Organization (WHO) defined non-severe CAP, amoxycillin compared with co-trimoxazole had similar failure rates (odds ratio (OR) 1.18, 95% confidence interval (CI) 0.91 to 1.51) and cure rates (OR 1.03, 95% CI 0.56 to 1.89). Three studies involved 3952 children.In children with severe pneumonia without hypoxaemia, oral antibiotics (amoxycillin/co-trimoxazole) compared with injectable penicillin had similar failure rates (OR 0.84, 95% CI 0.56 to 1.24), hospitalisation rates (OR 1.13, 95% CI 0.38 to 3.34) and relapse rates (OR 1.28, 95% CI 0.34 to 4.82). Six studies involved 4331 children below 18 years of age.In very severe CAP, death rates were higher in children receiving chloramphenicol compared to those receiving penicillin/ampicillin plus gentamicin (OR 1.25, 95% CI 0.76 to 2.07). One study involved 1116 children. For treatment of patients with CAP in ambulatory settings, amoxycillin is an alternative to co-trimoxazole. With limited data on other antibiotics, co-amoxyclavu
doi_str_mv 10.1002/14651858.CD004874.pub4
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7017636</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1381099420</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4734-6f71160393800a19d14e3d9748875fc6cab4f194d5dcda56c100cb43c001a1ce3</originalsourceid><addsrcrecordid>eNpVkEtLAzEUhYMgtlb_Qpmlm6m5TSaPjVDqEwpuFNyFTJKxkZmkTWaE_nsHrKKruziH7-NchOaAF4Dx8hooq0BUYrG-xZgKThe7oaYnaDoGsqSSvE3Qec4fGBMJIM7QZEk4IYRVUyRWofe1j703uWhiKkzsuiH4_lBqsx98crbYBTd0MXhd-FCYrW9tcuECnTa6ze7yeGfo9f7uZf1Ybp4fntarTWkoJ7RkDQdgo5gIjDVIC9QRKzkVgleNYUbXtAFJbWWN1RUz4yJTU2IwBg3GkRm6-eaOmzpnjQt90q3aJd_pdFBRe_U_CX6r3uOn4hg4I2wEXB0BKe4Hl3vV-Wxc2-rg4pAVEAFYSrrEY3X-1_Ur-XkX-QL3SG1F</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1381099420</pqid></control><display><type>article</type><title>Antibiotics for community-acquired pneumonia in children</title><source>Alma/SFX Local Collection</source><creator>Lodha, Rakesh ; Kabra, Sushil K ; Pandey, Ravindra M</creator><creatorcontrib>Lodha, Rakesh ; Kabra, Sushil K ; Pandey, Ravindra M</creatorcontrib><description>Pneumonia caused by bacterial pathogens is the leading cause of mortality in children in low-income countries. Early administration of antibiotics improves outcomes. To identify effective antibiotic drug therapies for community-acquired pneumonia (CAP) of varying severity in children by comparing various antibiotics. We searched CENTRAL 2012, Issue 10; MEDLINE (1966 to October week 4, 2012); EMBASE (1990 to November 2012); CINAHL (2009 to November 2012); Web of Science (2009 to November 2012) and LILACS (2009 to November 2012). Randomised controlled trials (RCTs) in children of either sex, comparing at least two antibiotics for CAP within hospital or ambulatory (outpatient) settings. Two review authors independently extracted data from the full articles of selected studies. We included 29 trials, which enrolled 14,188 children, comparing multiple antibiotics. None compared antibiotics with placebo.Assessment of quality of study revealed that 5 out of 29 studies were double-blind and allocation concealment was adequate. Another 12 studies were unblinded but had adequate allocation concealment, classifying them as good quality studies. There was more than one study comparing co-trimoxazole with amoxycillin, oral amoxycillin with injectable penicillin/ampicillin and chloramphenicol with ampicillin/penicillin and studies were of good quality, suggesting the evidence for these comparisons was of high quality compared to other comparisons.In ambulatory settings, for treatment of World Health Organization (WHO) defined non-severe CAP, amoxycillin compared with co-trimoxazole had similar failure rates (odds ratio (OR) 1.18, 95% confidence interval (CI) 0.91 to 1.51) and cure rates (OR 1.03, 95% CI 0.56 to 1.89). Three studies involved 3952 children.In children with severe pneumonia without hypoxaemia, oral antibiotics (amoxycillin/co-trimoxazole) compared with injectable penicillin had similar failure rates (OR 0.84, 95% CI 0.56 to 1.24), hospitalisation rates (OR 1.13, 95% CI 0.38 to 3.34) and relapse rates (OR 1.28, 95% CI 0.34 to 4.82). Six studies involved 4331 children below 18 years of age.In very severe CAP, death rates were higher in children receiving chloramphenicol compared to those receiving penicillin/ampicillin plus gentamicin (OR 1.25, 95% CI 0.76 to 2.07). One study involved 1116 children. For treatment of patients with CAP in ambulatory settings, amoxycillin is an alternative to co-trimoxazole. With limited data on other antibiotics, co-amoxyclavulanic acid and cefpodoxime may be alternative second-line drugs. Children with severe pneumonia without hypoxaemia can be treated with oral amoxycillin in an ambulatory setting. For children hospitalised with severe and very severe CAP, penicillin/ampicillin plus gentamycin is superior to chloramphenicol. The other alternative drugs for such patients are co-amoxyclavulanic acid and cefuroxime. Until more studies are available, these can be used as second-line therapies.There is a need for more studies with radiographically confirmed pneumonia in larger patient populations and similar methodologies to compare newer antibiotics. Recommendations in this review are applicable to countries with high case fatalities due to pneumonia in children without underlying morbidities and where point of care tests for identification of aetiological agents for pneumonia are not available.</description><identifier>EISSN: 1469-493X</identifier><identifier>DOI: 10.1002/14651858.CD004874.pub4</identifier><identifier>PMID: 23733365</identifier><language>eng</language><publisher>England: John Wiley &amp; Sons, Ltd</publisher><subject>Adolescent ; Amoxicillin - therapeutic use ; Anti-Bacterial Agents - therapeutic use ; Child ; Child health ; Chloramphenicol - therapeutic use ; Community-Acquired Infections - drug therapy ; Drug Therapy, Combination - methods ; Gentamicins - therapeutic use ; Humans ; Infectious disease ; Lungs &amp; airways ; Penicillins - therapeutic use ; Pneumonia ; Pneumonia, Bacterial - drug therapy ; Randomized Controlled Trials as Topic ; Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use</subject><ispartof>Cochrane database of systematic reviews, 2013-06, Vol.2013 (6), p.CD004874-CD004874</ispartof><rights>Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4734-6f71160393800a19d14e3d9748875fc6cab4f194d5dcda56c100cb43c001a1ce3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23733365$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lodha, Rakesh</creatorcontrib><creatorcontrib>Kabra, Sushil K</creatorcontrib><creatorcontrib>Pandey, Ravindra M</creatorcontrib><title>Antibiotics for community-acquired pneumonia in children</title><title>Cochrane database of systematic reviews</title><addtitle>Cochrane Database Syst Rev</addtitle><description>Pneumonia caused by bacterial pathogens is the leading cause of mortality in children in low-income countries. Early administration of antibiotics improves outcomes. To identify effective antibiotic drug therapies for community-acquired pneumonia (CAP) of varying severity in children by comparing various antibiotics. We searched CENTRAL 2012, Issue 10; MEDLINE (1966 to October week 4, 2012); EMBASE (1990 to November 2012); CINAHL (2009 to November 2012); Web of Science (2009 to November 2012) and LILACS (2009 to November 2012). Randomised controlled trials (RCTs) in children of either sex, comparing at least two antibiotics for CAP within hospital or ambulatory (outpatient) settings. Two review authors independently extracted data from the full articles of selected studies. We included 29 trials, which enrolled 14,188 children, comparing multiple antibiotics. None compared antibiotics with placebo.Assessment of quality of study revealed that 5 out of 29 studies were double-blind and allocation concealment was adequate. Another 12 studies were unblinded but had adequate allocation concealment, classifying them as good quality studies. There was more than one study comparing co-trimoxazole with amoxycillin, oral amoxycillin with injectable penicillin/ampicillin and chloramphenicol with ampicillin/penicillin and studies were of good quality, suggesting the evidence for these comparisons was of high quality compared to other comparisons.In ambulatory settings, for treatment of World Health Organization (WHO) defined non-severe CAP, amoxycillin compared with co-trimoxazole had similar failure rates (odds ratio (OR) 1.18, 95% confidence interval (CI) 0.91 to 1.51) and cure rates (OR 1.03, 95% CI 0.56 to 1.89). Three studies involved 3952 children.In children with severe pneumonia without hypoxaemia, oral antibiotics (amoxycillin/co-trimoxazole) compared with injectable penicillin had similar failure rates (OR 0.84, 95% CI 0.56 to 1.24), hospitalisation rates (OR 1.13, 95% CI 0.38 to 3.34) and relapse rates (OR 1.28, 95% CI 0.34 to 4.82). Six studies involved 4331 children below 18 years of age.In very severe CAP, death rates were higher in children receiving chloramphenicol compared to those receiving penicillin/ampicillin plus gentamicin (OR 1.25, 95% CI 0.76 to 2.07). One study involved 1116 children. For treatment of patients with CAP in ambulatory settings, amoxycillin is an alternative to co-trimoxazole. With limited data on other antibiotics, co-amoxyclavulanic acid and cefpodoxime may be alternative second-line drugs. Children with severe pneumonia without hypoxaemia can be treated with oral amoxycillin in an ambulatory setting. For children hospitalised with severe and very severe CAP, penicillin/ampicillin plus gentamycin is superior to chloramphenicol. The other alternative drugs for such patients are co-amoxyclavulanic acid and cefuroxime. Until more studies are available, these can be used as second-line therapies.There is a need for more studies with radiographically confirmed pneumonia in larger patient populations and similar methodologies to compare newer antibiotics. Recommendations in this review are applicable to countries with high case fatalities due to pneumonia in children without underlying morbidities and where point of care tests for identification of aetiological agents for pneumonia are not available.</description><subject>Adolescent</subject><subject>Amoxicillin - therapeutic use</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Child</subject><subject>Child health</subject><subject>Chloramphenicol - therapeutic use</subject><subject>Community-Acquired Infections - drug therapy</subject><subject>Drug Therapy, Combination - methods</subject><subject>Gentamicins - therapeutic use</subject><subject>Humans</subject><subject>Infectious disease</subject><subject>Lungs &amp; airways</subject><subject>Penicillins - therapeutic use</subject><subject>Pneumonia</subject><subject>Pneumonia, Bacterial - drug therapy</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use</subject><issn>1469-493X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNpVkEtLAzEUhYMgtlb_Qpmlm6m5TSaPjVDqEwpuFNyFTJKxkZmkTWaE_nsHrKKruziH7-NchOaAF4Dx8hooq0BUYrG-xZgKThe7oaYnaDoGsqSSvE3Qec4fGBMJIM7QZEk4IYRVUyRWofe1j703uWhiKkzsuiH4_lBqsx98crbYBTd0MXhd-FCYrW9tcuECnTa6ze7yeGfo9f7uZf1Ybp4fntarTWkoJ7RkDQdgo5gIjDVIC9QRKzkVgleNYUbXtAFJbWWN1RUz4yJTU2IwBg3GkRm6-eaOmzpnjQt90q3aJd_pdFBRe_U_CX6r3uOn4hg4I2wEXB0BKe4Hl3vV-Wxc2-rg4pAVEAFYSrrEY3X-1_Ur-XkX-QL3SG1F</recordid><startdate>20130604</startdate><enddate>20130604</enddate><creator>Lodha, Rakesh</creator><creator>Kabra, Sushil K</creator><creator>Pandey, Ravindra M</creator><general>John Wiley &amp; Sons, Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130604</creationdate><title>Antibiotics for community-acquired pneumonia in children</title><author>Lodha, Rakesh ; Kabra, Sushil K ; Pandey, Ravindra M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4734-6f71160393800a19d14e3d9748875fc6cab4f194d5dcda56c100cb43c001a1ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Amoxicillin - therapeutic use</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Child</topic><topic>Child health</topic><topic>Chloramphenicol - therapeutic use</topic><topic>Community-Acquired Infections - drug therapy</topic><topic>Drug Therapy, Combination - methods</topic><topic>Gentamicins - therapeutic use</topic><topic>Humans</topic><topic>Infectious disease</topic><topic>Lungs &amp; airways</topic><topic>Penicillins - therapeutic use</topic><topic>Pneumonia</topic><topic>Pneumonia, Bacterial - drug therapy</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lodha, Rakesh</creatorcontrib><creatorcontrib>Kabra, Sushil K</creatorcontrib><creatorcontrib>Pandey, Ravindra M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cochrane database of systematic reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lodha, Rakesh</au><au>Kabra, Sushil K</au><au>Pandey, Ravindra M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibiotics for community-acquired pneumonia in children</atitle><jtitle>Cochrane database of systematic reviews</jtitle><addtitle>Cochrane Database Syst Rev</addtitle><date>2013-06-04</date><risdate>2013</risdate><volume>2013</volume><issue>6</issue><spage>CD004874</spage><epage>CD004874</epage><pages>CD004874-CD004874</pages><eissn>1469-493X</eissn><abstract>Pneumonia caused by bacterial pathogens is the leading cause of mortality in children in low-income countries. Early administration of antibiotics improves outcomes. To identify effective antibiotic drug therapies for community-acquired pneumonia (CAP) of varying severity in children by comparing various antibiotics. We searched CENTRAL 2012, Issue 10; MEDLINE (1966 to October week 4, 2012); EMBASE (1990 to November 2012); CINAHL (2009 to November 2012); Web of Science (2009 to November 2012) and LILACS (2009 to November 2012). Randomised controlled trials (RCTs) in children of either sex, comparing at least two antibiotics for CAP within hospital or ambulatory (outpatient) settings. Two review authors independently extracted data from the full articles of selected studies. We included 29 trials, which enrolled 14,188 children, comparing multiple antibiotics. None compared antibiotics with placebo.Assessment of quality of study revealed that 5 out of 29 studies were double-blind and allocation concealment was adequate. Another 12 studies were unblinded but had adequate allocation concealment, classifying them as good quality studies. There was more than one study comparing co-trimoxazole with amoxycillin, oral amoxycillin with injectable penicillin/ampicillin and chloramphenicol with ampicillin/penicillin and studies were of good quality, suggesting the evidence for these comparisons was of high quality compared to other comparisons.In ambulatory settings, for treatment of World Health Organization (WHO) defined non-severe CAP, amoxycillin compared with co-trimoxazole had similar failure rates (odds ratio (OR) 1.18, 95% confidence interval (CI) 0.91 to 1.51) and cure rates (OR 1.03, 95% CI 0.56 to 1.89). Three studies involved 3952 children.In children with severe pneumonia without hypoxaemia, oral antibiotics (amoxycillin/co-trimoxazole) compared with injectable penicillin had similar failure rates (OR 0.84, 95% CI 0.56 to 1.24), hospitalisation rates (OR 1.13, 95% CI 0.38 to 3.34) and relapse rates (OR 1.28, 95% CI 0.34 to 4.82). Six studies involved 4331 children below 18 years of age.In very severe CAP, death rates were higher in children receiving chloramphenicol compared to those receiving penicillin/ampicillin plus gentamicin (OR 1.25, 95% CI 0.76 to 2.07). One study involved 1116 children. For treatment of patients with CAP in ambulatory settings, amoxycillin is an alternative to co-trimoxazole. With limited data on other antibiotics, co-amoxyclavulanic acid and cefpodoxime may be alternative second-line drugs. Children with severe pneumonia without hypoxaemia can be treated with oral amoxycillin in an ambulatory setting. For children hospitalised with severe and very severe CAP, penicillin/ampicillin plus gentamycin is superior to chloramphenicol. The other alternative drugs for such patients are co-amoxyclavulanic acid and cefuroxime. Until more studies are available, these can be used as second-line therapies.There is a need for more studies with radiographically confirmed pneumonia in larger patient populations and similar methodologies to compare newer antibiotics. Recommendations in this review are applicable to countries with high case fatalities due to pneumonia in children without underlying morbidities and where point of care tests for identification of aetiological agents for pneumonia are not available.</abstract><cop>England</cop><pub>John Wiley &amp; Sons, Ltd</pub><pmid>23733365</pmid><doi>10.1002/14651858.CD004874.pub4</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 1469-493X
ispartof Cochrane database of systematic reviews, 2013-06, Vol.2013 (6), p.CD004874-CD004874
issn 1469-493X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7017636
source Alma/SFX Local Collection
subjects Adolescent
Amoxicillin - therapeutic use
Anti-Bacterial Agents - therapeutic use
Child
Child health
Chloramphenicol - therapeutic use
Community-Acquired Infections - drug therapy
Drug Therapy, Combination - methods
Gentamicins - therapeutic use
Humans
Infectious disease
Lungs & airways
Penicillins - therapeutic use
Pneumonia
Pneumonia, Bacterial - drug therapy
Randomized Controlled Trials as Topic
Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use
title Antibiotics for community-acquired pneumonia in children
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T14%3A55%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibiotics%20for%20community-acquired%20pneumonia%20in%20children&rft.jtitle=Cochrane%20database%20of%20systematic%20reviews&rft.au=Lodha,%20Rakesh&rft.date=2013-06-04&rft.volume=2013&rft.issue=6&rft.spage=CD004874&rft.epage=CD004874&rft.pages=CD004874-CD004874&rft.eissn=1469-493X&rft_id=info:doi/10.1002/14651858.CD004874.pub4&rft_dat=%3Cproquest_pubme%3E1381099420%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4734-6f71160393800a19d14e3d9748875fc6cab4f194d5dcda56c100cb43c001a1ce3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1381099420&rft_id=info:pmid/23733365&rfr_iscdi=true